Highlights From the American Heart Association’s Scientific Sessions 2022
JAMA Medical News
00:00
Atherosclerosis - Is There a Risk of Heart Attacks?
Pnefibrate was studied in a large randomized trial to see if it could reduce triglycerides. It also had a mechanism maybe to increase HDL and see if that reduced cardiovascular events. The mace event point wasn't changed at all. Yet fibrates are the second most prescribed medication after statins for lipid therapy. So I do think it was a very informing of practice that there should be other things we think about.
Transcript
Play full episode
